Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVGN6051 + Toripalimab + Paclitaxel in Recurrent/Metastatic HNSCC
NCT06378177Phase 2Active, not recruiting
- Sponsor
- Lijin Biomedical Technology
- Start
- Jun 2024
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of exlinkibart in head and neck squamous cell carcinoma (HNSCC), sponsored by Lijin Biomedical Technology. Started Jun 2024; status: active, not recruiting.
02
Drugs
exlinkibart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06378177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378177.